Warfarin anticoagulation reversal: Management of the asymptomatic and bleeding patient

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 2, 2010, Pages 171-181

  Makris, Michael ^a,b   Van Veen, Joost J ^a   MacLean, Rhona ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation reversal; Hemorrhage; Prothrombin complex concentrate; Recombinant factor VIIa; Vitamin K; Warfarin

Indexed keywords

FRESH FROZEN PLASMA; MENADIOL; PHYTOMENADIONE; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEMOPHILIA A; HUMAN; HYPERVOLEMIA; INFECTION; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FACTOR VIIA; HEMORRHAGE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 77949913996     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0412-5     Document Type: Conference Paper

References (67)

1. S Schulman C Kearon 2005 Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 4 692 694 10.1111/j.1538-7836.2005.01204.x 1:STN:280: DC%2BD2M3gvFamtA%3D%3D 15842354 (Pubitemid 41647882)
2. G Palareti N Leali S Coccheri, et al. 1996 Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Lancet 348 9025 423 428 10.1016/S0140-6736(96)01109-9 1:CAS:528:DyaK28XlsValtrY%3D 8709780 (Pubitemid 26267872)
3. AS Go EM Hylek Y Chang, et al. 2003 Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 20 2685 2692 10.1001/jama.290.20.2685 1:CAS:528:DC%2BD3sXpsVakt78%3D 14645310 (Pubitemid 37475596)
4. D Poli E Antonucci E Grifoni, et al. 2009 Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention Thromb Haemost 101 2 367 372 1:CAS:528:DC%2BD1MXjtVyrurs%3D 19190823
5. D Ost J Tepper H Mihara, et al. 2005 Duration of anticoagulation following venous thromboembolism: a meta-analysis JAMA 294 6 706 715 10.1001/jama.294.6.706 1:CAS:528:DC%2BD2MXns1CjsbY%3D 16091573 (Pubitemid 41159290)
6. L Poller M Keown S Ibrahim, et al. 2009 A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program Thromb Haemost 101 3 487 494 1:CAS:528:DC%2BD1MXjslSnt7c%3D 19277410
7. C Kearon JS Ginsberg MJ Kovacs, et al. 2003 Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N Engl J Med 349 7 631 639 10.1056/NEJMoa035422 1:CAS:528:DC%2BD3sXmtl2gsrs%3D 12917299 (Pubitemid 36975995)
8. SC Cannegieter FR Rosendaal AR Wintzen, et al. 1995 Optimal oral anticoagulant therapy in patients with mechanical heart valves N Engl J Med 333 1 11 17 10.1056/NEJM199507063330103 1:STN:280:DyaK2M3psFOmtw%3D%3D 7776988
9. MA Crowther JS Ginsberg J Julian, et al. 2003 A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome N Engl J Med 349 12 1133 1138 10.1056/NEJMoa035241 1:CAS:528:DC%2BD3sXnsV2jtb4%3D 13679527 (Pubitemid 37122325)
10. M Torn FJ van der Meer FR Rosendaal 2004 Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism Arch Intern Med 164 6 668 673 10.1001/archinte.164.6.668 1:CAS:528: DC%2BD2cXjt1eqtLs%3D 15037497 (Pubitemid 38392983)
11. Y van Leeuwen FR Rosendaal SC Cannegieter 2008 Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants J Thromb Haemost 6 3 451 456 10.1111/j.1538-7836.2007. 02874.x 18088347
12. BA Hutten AW Lensing RA Kraaijenhagen, et al. 1999 Safety of treatment with oral anticoagulants in the elderly. A systematic review Drugs Aging 14 4 303 312 10.2165/00002512-199914040-00005 1:CAS:528:DyaK1MXjtFKnsb4%3D 10319243 (Pubitemid 29195346)
13. N Kagansky H Knobler E Rimon, et al. 2004 Safety of anticoagulation therapy in well-informed older patients Arch Intern Med 164 18 2044 2050 10.1001/archinte.164.18.2044 15477441 (Pubitemid 39390563)
14. RG Hart O Benavente LA Pearce 1999 Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis Cerebrovasc Dis 9 4 215 217 10.1159/000015958 1:STN:280: DyaK1Mzit1Chuw%3D%3D 10393408 (Pubitemid 29308806)
15. JJ Glasheen RV Fugit AV Prochazka 2005 The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens J Gen Intern Med 20 7 653 656 10.1007/s11606-005-0113-5 16050864
16. S Schulman RJ Beyth C Kearon, et al. 2008 Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 257S 298S 10.1378/chest.08-0674 1:CAS:528:DC%2BD1cXptVKhsr4%3D 18574268
17. RH White RJ Beyth H Zhou, et al. 1999 Major bleeding after hospitalization for deep-venous thrombosis Am J Med 107 5 414 424 10.1016/S0002-9343(99)00267-3 1:STN:280:DC%2BD3c%2FjsVGrsQ%3D%3D 10569295 (Pubitemid 29528329)
18. SD Fihn CM Callahan DC Martin, et al. 1996 The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics Ann Intern Med 124 11 970 979 1:STN:280:DyaK283ht1egsA%3D%3D 8624064
19. KN Kangelaris S Bent RL Nussbaum, et al. 2009 Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin J Gen Intern Med 24 5 656 664 10.1007/s11606-009-0949-1 19306050
20. CS Landefeld L Goldman 1989 Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am J Med 87 2 144 152 10.1016/S0002-9343(89)80689-8 1:STN:280: DyaL1MzjtlOktg%3D%3D 2787958
21. RJ Beyth LM Quinn CS Landefeld 1998 Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 2 91 99 10.1016/S0002-9343(98)00198-3 1:CAS:528:DyaK1cXlvVamsr4%3D 9727814 (Pubitemid 28405230)
22. PM Kuijer BA Hutten MH Prins, et al. 1999 Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch Intern Med 159 5 457 460 10.1001/archinte.159.5.457 1:STN:280:DyaK1M7ntlanug%3D%3D 10074953 (Pubitemid 29108910)
23. BF Gage Y Yan PE Milligan, et al. 2006 Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 3 713 719 10.1016/j.ahj.2005.04.017 16504638 (Pubitemid 43290267)
24. EM Hylek Y Chang SJ Skates, et al. 2000 Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation Arch Intern Med 160 11 1612 1617 10.1001/archinte.160.11.1612 1:CAS:528:DC%2BD3cXktlGktb0%3D 10847254
25. W Ageno M Crowther L Steidl, et al. 2002 Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial Thromb Haemost 88 1 48 51 1:CAS:528:DC%2BD38XlslKmtLk%3D 12152676
26. CG Fondevila SH Grosso MT Santarelli, et al. 2001 Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study Blood Coagul Fibrinolysis 12 1 9 16 10.1097/00001721-200101000-00002 1:CAS:528:DC%2BD3MXhtVaqsL0%3D 11229833 (Pubitemid 32150246)
27. D Poli E Antonucci A Lombardi, et al. 2003 Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation Haematologica 88 2 237 238 1:CAS:528:DC%2BD3sXotlGhu7k%3D 12604423
28. JJ Glover GB Morrill 1995 Conservative treatment of overanticoagulated patients Chest 108 4 987 990 10.1378/chest.108.4.987 1:STN:280: DyaK28%2FhtVWmtQ%3D%3D 7555174
29. TR Lousberg DM Witt DG Beall, et al. 1998 Evaluation of excessive anticoagulation in a group model health maintenance organization Arch Intern Med 158 5 528 534 10.1001/archinte.158.5.528 1:STN:280:DyaK1c7mslKmtA%3D%3D 9508231
30. DA Garcia S Regan M Crowther, et al. 2006 The risk of hemorrhage among patients with warfarin-associated coagulopathy J Am Coll Cardiol 47 4 804 808 10.1016/j.jacc.2005.09.058 1:CAS:528:DC%2BD28XhsFCqtbw%3D 16487849 (Pubitemid 43243105)
31. EM Hylek S Regan AS Go, et al. 2001 Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin Ann Intern Med 135 6 393 400 1:STN:280:DC%2BD3MrislSgsg%3D%3D 11560452
32. MA Crowther J Julian D McCarty, et al. 2000 Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial Lancet 356 9241 1551 1553 10.1016/S0140-6736(00)03125-1 1:CAS:528:DC%2BD3cXot12lsb0%3D 11075768
33. V Pengo A Banzato E Garelli, et al. 1993 Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation Blood Coagul Fibrinolysis 4 5 739 741 1:CAS:528:DyaK2cXis1Srurk%3D 8292723
34. W Ageno D Garcia M Silingardi, et al. 2005 A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves J Am Coll Cardiol 46 4 732 733 10.1016/j.jacc.2005.05.022 1:CAS:528:DC%2BD2MXns1Whurs%3D 16098445 (Pubitemid 41132707)
35. RJ Patel DM Witt JJ Saseen, et al. 2000 Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation Pharmacotherapy 20 10 1159 1166 10.1592/phco.20.15.1159.34585 1:CAS:528:DC%2BD3cXnsFChsrk%3D 11034038
36. CW Fetrow T Overlock L Leff 1997 Antagonism of warfarin-induced hypoprothrombinemia with use of low-dose subcutaneous vitamin K1 J Clin Pharmacol 37 8 751 757 1:CAS:528:DyaK2sXlvFelsbo%3D 9378848
37. MA Crowther D Donovan L Harrison, et al. 1998 Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin Thromb Haemost 79 6 1116 1118 1:CAS:528:DyaK1cXjvVWmu7g%3D 9657434
38. TM Duong BK Plowman AP Morreale, et al. 1998 Retrospective and prospective analyses of the treatment of overanticoagulated patients Pharmacotherapy 18 6 1264 1270 1:STN:280:DyaK1M%2FntV2ltQ%3D%3D 9855325
39. K Pendry M Bhavnani K Shwe 2001 The use of oral vitamin K for reversal of over-warfarinization Br J Haematol 113 3 839 840 10.1046/j.1365-2141.2001. 02804.x 1:STN:280:DC%2BD3M3pvVGnsg%3D%3D 11380479 (Pubitemid 32524412)
40. HG Watson TP Baglin M Makris 2002 The use of oral vitamin K for reversal of over-warfarinization Br J Haematol 116 1 237 10.1046/j.1365-2141.2002.3242-2. x 11848091
41. HG Watson T Baglin SL Laidlaw, et al. 2001 A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin Br J Haematol 115 1 145 149 10.1046/j.1365-2141.2001.03070.x 1:CAS:528:DC%2BD3MXotFWmsbY%3D 11722425 (Pubitemid 32995108)
42. AM Lubetsky HM Yonath DM Olchovsky, et al. 2003 Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study Arch Intern Med 163 20 2469 2473 10.1001/archinte.163.20.2469 1:CAS:528:DC%2BD3sXpvVyisbY%3D 14609783 (Pubitemid 37385789)
43. A Hung S Singh RC Tait 2000 A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization Br J Haematol 109 3 537 539 10.1046/j.1365-2141.2000.02001.x 1:CAS:528: DC%2BD3cXkvVWkt70%3D 10886201 (Pubitemid 30415179)
44. MT Brophy LD Fiore D Deykin 1997 Low-dose vitamin K therapy in excessively anticoagulated patients: a dose-finding study J Thromb Thrombolysis 4 2 289 292 10.1023/A:1008811421946 1:CAS:528:DyaK2sXis1Smur8%3D 10639272 (Pubitemid 27120977)
45. HG Shetty G Backhouse DP Bentley, et al. 1992 Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1 Thromb Haemost 67 1 13 15 1:STN:280:DyaK38zhtFygsw%3D%3D 1615468
46. MA Crowther JD Douketis T Schnurr, et al. 2002 Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial Ann Intern Med 137 4 251 254 1:CAS:528:DC%2BD38XmvFChsLw%3D 12186515
47. R Nee D Doppenschmidt DJ Donovan, et al. 1999 Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation Am J Cardiol 83 2 286 287 10.1016/S0002-9149(98)00842-X 1:CAS:528:DyaK1MXpvV2ltw%3D%3D 10073841 (Pubitemid 29047318)
48. G Raj R Kumar WP McKinney 1999 Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione Arch Intern Med 159 22 2721 2724 10.1001/archinte.159.22.2721 1:CAS:528:DC%2BD3cXhsVersw%3D%3D 10597763
49. DC Byrd MA Stephens GL Hamann, et al. 1999 Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio Am J Health Syst Pharm 56 22 2312 2315 1:CAS:528:DyaK1MXnvFans7g%3D 10582823
50. KJ DeZee WT Shimeall KM Douglas, et al. 2006 Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis Arch Intern Med 166 4 391 397 10.1001/.391 1:CAS:528:DC%2BD28Xitl2qtL8%3D 16505257 (Pubitemid 43313641)
51. DL Riegert-Johnson GW Volcheck 2002 The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review Ann Allergy Asthma Immunol 89 4 400 406 1:CAS:528:DC%2BD3sXntl2hsb0%3D 12392385
52. F Dentali MA Crowther 2008 Management of excessive anticoagulant effect due to vitamin K antagonists Hematology Am Soc Hematol Educ Program 2008 266 270
53. MA Crowther W Ageno D Garcia, et al. 2009 Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial Ann Intern Med 150 5 293 300 19258557
54. A Lubetsky Y Shasha D Olchovsky, et al. 2003 Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation Thromb Haemost 90 1 71 76 1:CAS:528:DC%2BD3sXls1Wmurc%3D 12876628
55. B Ozgonenel B O'Malley P Krishen, et al. 2007 Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital Am J Hematol 82 12 1091 1094 10.1002/ajh.20902 17674360 (Pubitemid 350209852)
56. SB Lee EM Manno KF Layton, et al. 2006 Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP Neurology 67 7 1272 1274 10.1212/01.wnl.0000238104.75563.2f 1:CAS:528:DC%2BD28XhtFyqtb7N 17030765 (Pubitemid 44566354)
57. B Vigue C Ract B Tremey, et al. 2007 Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage Intensive Care Med 33 4 721 725 10.1007/s00134-007-0528-z 1:CAS:528:DC%2BD1cXhtV2ltr%2FP 17260127 (Pubitemid 46474890)
58. M Makris M Greaves WS Phillips, et al. 1997 Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy Thromb Haemost 77 3 477 480 1:CAS:528:DyaK2sXitVemtLk%3D 9065997
59. NM Boulis MP Bobek A Schmaier, et al. 1999 Use of factor IX complex in warfarin-related intracranial hemorrhage Neurosurgery 45 5 1113 1118 10.1097/00006123-199911000-00020 1:STN:280:DC%2BD3c%2Fhs1Whsg%3D%3D 10549927 (Pubitemid 29517515)
60. M Cartmill G Dolan JL Byrne, et al. 2000 Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies Br J Neurosurg 14 5 458 461 10.1080/02688690050175265 1:STN:280:DC%2BD3M7hsl2itA%3D%3D 11198768
61. K Fredriksson B Norrving LG Stromblad 1992 Emergency reversal of anticoagulation after intracerebral hemorrhage Stroke 23 7 972 977 1:STN:280:DyaK38zhtF2rsQ%3D%3D 1615547
62. CA Leissinger PM Blatt WK Hoots, et al. 2008 Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature Am J Hematol 83 2 137 143 10.1002/ajh.21046 1:CAS:528:DC%2BD1cXitFKrs78%3D 17729241
63. I Pabinger B Brenner U Kalina, et al. 2008 Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial J Thromb Haemost 6 4 622 631 10.1111/j.1538-7836. 2008.02904.x 1:CAS:528:DC%2BD1cXltFCqs78%3D 18208533
64. L Holland TE Warkentin M Refaai, et al. 2009 Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose Transfusion 49 1171 1177 10.1111/j.1537-2995.2008.02080.x 1:CAS:528: DC%2BD1MXotFOmsb0%3D 19210325
65. RP Rosovsky MA Crowther 2008 What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? Hematology Am Soc Hematol Educ Program 2008 36 38
66. CC Hsia IH Chin-Yee VC McAlister 2008 Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials Ann Surg 248 1 61 68 10.1097/SLA.0b013e318176c4ec 18580208
67. J Ansell J Hirsh E Hylek, et al. 2008 Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 160S 198S 10.1378/chest.08-0670 1:CAS:528:DC%2BD1cXptVKiu7o%3D 18574265